Systematic review: The role of tacrolimus in the management of Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 11-12, 2011, Pages 1282-1294

  McSharry, K ^a   Dalzell, A M ^a   Leiper, K ^b   El Matary, W ^c,d  

^a ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF MANITOBA   (Canada)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; THALIDOMIDE;

ASTHENIA; CASE STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CROHN DISEASE; CYSTIC FIBROSIS; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; HEADACHE; HUMAN; HYPERKALEMIA; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; LUMINAL CROHN DISEASE; MALAISE; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PERIANAL CROHN DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS;

CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 81355160293     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04873.x     Document Type: Review

References (39)

1. Crohn BB, Ginzburg L, Oppenheimer GD,. Regional ileitis: a pathological clinical entity. JAMA 1932; 99: 1323-9.
2. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40: 955-62.
3. Braat H, Peppelenbosch MP, Hommes DW,. Immunology of Crohn's disease. Ann N Y Acad Sci 2006; 1072: 135-54.
4. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe. Is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-7.
5. Moum B, Vatn MH, Ekbom A,. Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eaterns Norway (IBSEN) Study Group of Gastroenterologists. Scan J Gastroenterol 1996; 31: 355-61.
6. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted Country, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-61.
7. Loftus EV, Schoenfeld P, Sandborn WJ,. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60.
8. Shanahan E, Bernstein CN,. The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol 2009; 25: 301-5.
9. Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease: results of a large, prospective population- based study in southeastern Norway, 1990-93. Scan J Gastroenterol 1997; 32: 1005-12.
10. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57.
11. Romberg-Camps MJ, Dagneli PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-83.
12. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterolgoy Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112-24.
13. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ,. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
14. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J,. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5 year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-30.
15. Peyrin-Biroulet L, Lémann M,. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 870-9.
16. Stange EF, Travis SPL, Vermeire S, et al. European evidence based guidelines on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl. 1): i16-35.
17. Carter MJ, Lobo AJ, Travis SPL,. British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: v1-16.
18. Busuttil RW, Lake JR,. Role of tacrolimus in the evolution of liver transplantation. Transplantation 2004; 77: S44-51.
19. Vincenti F,. A decade of progress in kidney transplantation. Transplantation 2004; 77: S52-61.
20. Goulet O, Michael JL, Jobert A, et al. Small bowel transplantation alone or with the liver in children: changes using FK506. Transplant Proc 1998; 30: 1569-70.
21. Rusnak F, Mertz P,. Calcineurin: form and function. Physiol Rev 2000; 80: 1483-521.
22. Wong SH,. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta 2001; 313: 241-53.
23. Ruzicka T, Assmann T, Homey B,. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-80.
24. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W,. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-23.
25. Gonzalez-Lama Y, Gisbert JP, Mate J,. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006; 51: 1833-40.
26. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
27. Higgins JPT, Altman DG,. Chapter 8: Assessing risk of bias in included studies. In:, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available at: http://www.cochrane-handbook.org.
28. National Institute for Health and Clinical Excellence (NICE). Quality of case series. Available at:. Accessed January 11, 2011.
29. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15: 371-7.
30. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomised, placebo-controlled trial. Gastroenterology 2003; 125: 380-8.
31. Gonzalez-Lama Y, Abreu L, Vera MI, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis 2005; 11: 8-15.
32. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ,. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 239-45.
33. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH,. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47: 436-40.
34. Baumgart DC, Wiedenmann B, Dignass AU,. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 1273-81.
35. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU,. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease-a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-56.
36. Ng SC, Arebi N, Kamm MA,. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 129-34.
37. Hart AL, Plamondon S, Kamm MA,. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007; 13: 245-53.
38. Benson A, Barrett T, Sparberg M, Buchman AL,. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12.
39. Tamaki H, Nakase H, Matsuura M, et al. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. J Gastroenterol 2008; 43: 774-9.